Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162414 | 0.89 | HPGD (0.69) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL8894839 | 0.86 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL8980587 | 0.86 | ALDH1A1 (0.55) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL31686014 | 0.85 | HPGD (0.64) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL11230535 | 0.85 | HPGD (0.64) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL461599 | 0.85 | HPGD (0.64) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL9492896 | 0.85 | HPGD (0.77) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL10604035 | 0.85 | HPGD (0.66) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL13162943 | 0.84 | NPC1 (0.59) | HPGDSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL13162698 | 0.84 | HPGD (0.62) | HPGDSMN1; SMN2RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441686-B2 | Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists | BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240059655-A1 | HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS | UNIV TEXAS (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20050250707-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2005-11-10 | — | — | US | disclosed |
| US-6953858-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| EP-1448539-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | Agouron Pharmaceuticals , Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2002100845-A1 | HV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0695184-B1 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5863950-A | AMIDES OR THIO AMIDE COMPOUNDS WITH HYDROXY OR ETHER GROUPS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0695184-A4 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0695184-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994015608-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HPGD 3394/4885SMN1; SMN2 4512/4885RAB9A 1513/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HPGD 3242/4885SMN1; SMN2 4628/4885RAB9A 1490/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | HPGD 1908/4885SMN1; SMN2 4775/4885RAB9A 2309/4885 |
| US-12441686-B2 | Heterocyclic g-protein-coupled receptor 52 (GPR52) agonists | GPR52, GPR68, GPR65 | HPGD 979/4885SMN1; SMN2 2962/4885RAB9A 2341/4885 |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | SERPINB1, PEPD, PREP | HPGD 394/4885SMN1; SMN2 3736/4885RAB9A 2120/4885 |
| US-20240059655-A1 | HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS | GPR52, GPR68, GPR65 | HPGD 979/4885SMN1; SMN2 2962/4885RAB9A 2341/4885 |
| US-20050250707-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | HPGD 341/4885SMN1; SMN2 3932/4885RAB9A 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.